PatternsRadar
Sign in

KREBSBIOKrebs Biochemicals and Industries Limited

NSEASM Stage I
57.08INR-0.07 (-0.12%)Close · 20 Nov 2026
29 Oct 2026Last results
HealthcareSector
Pharmaceuticals & BiotechnologyIndustry
₹123 CrMarket cap
—P/E (TTM)
83.6%Delivery

Filings & corporate actions

41 results filed
CSV
Next results · Q3 FY27
Expected 3 Feb 2027 – 13 Feb 2027
Estimate: filed 34–44 days after quarter end, last 5 times
2026
  • 29 OctresultsResults · Q2 FY27 · standalone-2.1%NSE
  • 6 OctshareholdingShareholding · 30 Sept 2026-8.0%NSE
  • 6 AugresultsResults · Q1 FY27 · standalone+1.0%NSE
  • 8 JulshareholdingShareholding · 30 Jun 2026-7.1%NSE
  • 21 MayresultsResults · Q4 FY26 · standalone+5.0%NSE
  • 13 AprshareholdingShareholding · 31 Mar 20260.0%NSE
  • 9 FebresultsResults · Q3 FY26 · standalone-1.4%NSE
  • 5 JanshareholdingShareholding · 31 Dec 2025-2.0%NSE

Reaction to results · all yearsrose on day 0 in 9 of 76 CSV

QuarterFiledDay 0+5D+20DRel vol
Q2 FY2729 Oct 2026-2.1%-2.2%—0.1×
Q1 FY276 Aug 2026+1.0%+0.2%+2.6%1.1×
Q4 FY2621 May 2026+5.0%+14.3%+15.1%4.4×
Q3 FY269 Feb 2026-1.4%-0.2%-4.2%20.9×
Q2 FY264 Nov 2025+0.3%-1.8%-7.0%0.2×
Q1 FY267 Aug 2025-3.4%-1.5%-5.8%0.6×
Q4 FY2520 May 2025-1.1%-0.9%+19.6%1.7×
Q3 FY254 Feb 2025-2.9%-12.1%-18.7%0.3×
Q2 FY2511 Nov 2024-1.2%-6.5%+22.7%4.9×
Q1 FY257 Aug 2024-2.1%-7.4%-1.8%0.1×
Q4 FY2422 May 2024-3.2%-6.0%+6.2%3.7×
Q3 FY2412 Feb 2024-2.2%-0.7%-9.1%0.5×
Q2 FY248 Nov 2023-0.9%-3.7%-6.1%1.3×
Q1 FY249 Aug 2023-3.5%+9.6%-9.7%1.3×
Q4 FY2324 May 2023-3.6%-1.9%+10.4%0.9×
Q3 FY233 Feb 2023+1.3%-2.3%-28.1%7.4×
Q2 FY2311 Nov 2022-0.4%-4.3%+0.5%0.1×
Q1 FY231 Aug 2022-4.3%-6.8%+4.3%0.6×
Q4 FY2223 May 2022-7.5%-5.5%-17.0%2.6×
Q3 FY2213 Feb 2022-4.6%+8.0%+5.2%1.1×
Q2 FY2210 Nov 2021-1.5%+1.3%-3.9%0.5×
Q1 FY2230 Jul 2021-0.9%-1.4%+21.0%1.7×
Q4 FY2127 May 2021-1.5%-1.9%-7.2%0.7×
Q3 FY2130 Jan 2021-5.9%-6.8%-5.7%1.0×
Q2 FY215 Nov 2020-2.3%-0.3%+22.5%0.5×
Q1 FY217 Aug 2020-2.2%-5.0%-9.5%0.8×
Q4 FY2016 Jun 2020-3.9%-2.8%-11.3%0.3×
Q3 FY201 Feb 2020-1.8%+1.6%+6.6%0.9×
Q2 FY202 Nov 2019-6.1%-7.7%-6.2%1.5×
Q1 FY2010 Aug 2019-3.9%-5.8%+5.4%1.6×
Q4 FY1921 May 2019-0.9%-1.5%-13.8%0.5×
Q3 FY1927 Feb 2019+1.9%+5.7%+31.5%1.0×
Q2 FY199 Nov 2018+4.0%+5.5%+12.9%2.1×
Q1 FY198 Aug 2018-0.7%-0.9%+1.8%0.2×
Q4 FY1820 Jun 2018+2.3%-8.4%-9.4%0.1×
Q3 FY1816 Mar 2018-4.1%-7.2%-2.8%0.5×
Q2 FY1822 Nov 2017-3.4%-0.9%+1.0%0.7×
Q1 FY1821 Aug 2017+2.9%+3.5%-2.4%0.1×
Q4 FY1712 Jun 2017+4.6%+20.4%+1.3%4.2×
Q3 FY1711 Feb 2017-2.4%-0.6%-3.9%0.4×
Q2 FY178 Dec 2016-3.2%-11.3%-9.7%0.0×
Q1 FY1720 Sept 2016————
Q4 FY161 Jun 2016————
Q3 FY1613 Feb 2016————
Q2 FY169 Nov 2015————
Q1 FY1614 Aug 2015————
Q4 FY1530 May 2015————
Q3 FY1520 Feb 2015————
Q1 FY1521 Aug 2014————
Q4 FY1430 May 2014————
Q3 FY1427 Feb 2014————
Q4 FY136 Jun 2013————
Q3 FY1312 Feb 2013————
Q2 FY1312 Nov 2012————
Q1 FY1321 Aug 2012————
Q4 FY1218 May 2012————
Q3 FY1221 Feb 2012————
Q2 FY1214 Nov 2011————
Q1 FY1224 Aug 2011————
Q4 FY116 Jun 2011————
Q3 FY1116 Feb 2011————
Q2 FY111 Nov 2010————
Q1 FY1121 Jul 2010————
Q4 FY1024 May 2010————
Q3 FY1027 Jan 2010————
Q2 FY1026 Oct 2009————
Q1 FY1030 Jul 2009————
Q4 FY0929 May 2009————
Q3 FY0931 Jan 2009————
Q2 FY091 Nov 2008————
Q1 FY0925 Jul 2008————
Q4 FY0829 Apr 2008————
Q3 FY0822 Jan 2008————
Q2 FY0824 Oct 2007————
Q1 FY0827 Jul 2007————
Q4 FY074 Jun 2007————
Average-1.6%-1.4%-0.1%

Close-to-close from the session before the filing could trade. Day 0 is the first session after it.

Growth · Q2 FY27

Revenue YoY+38.9%
Profit YoY—
Interest cost YoY+14.2%
Revenue QoQ-17.1%
Profit QoQ—
CAGR2Y3Y4Y5Y6Y7Y
Revenue-27.2%-16.4%-21.4%-7.5%-8.3%-2.5%
Profit——————

Key data

Open57.72
Day range56.10 – 58.80
52-week range38.33 – 76.85
From 52w high-25.7%
RSI (14)47.5
ATR (14)3.44
Volume1.6K
Avg volume (20D)15.7K
Rel volume0.10×
Volatility (1Y)57.7%
Turnover₹89,217
Traded value (NSE)₹89,217
VWAP56.79
SMA 50 / 20058.19 / 57.57
Price band20%

Delivery percentage

Latest · 20 Nov 202683.6%
20-day avg73.7%
1-year avg74.4%
Percentile (own history)69th
Range1.8–100.0%
Sessions2,023

Over the last 20 sessions KREBSBIO settled 73.7% of its traded quantity, which is unusually high for an NSE equity. That is in line with its own one-year average of 74.4%. The latest session ranks higher than 69% of the 2,023 sessions on record for it.

What delivery percentage measuresScan the whole market on delivery

Dividends, deals & holders

Dividend yield0.00%
Dividend, trailing 12M₹0.00
Paid every year for0 yr
Shareholders8.5K · +0.1% QoQ
Net bulk deals, 30D0.00%
Block deals, 30D₹0
Last bulk buy50 days ago

Performance returns

1D1W1M3M6M1Y
Price-0.12%-3.63%-0.70%+3.41%+1.80%-17.48%

Valuation

Market cap₹123 Cr
Market cap (NSE)₹123 Cr
Free-float cap₹34 Cr
P/E (TTM)—
P/E (NSE)—
EPS (TTM)-6.19
P/B—
Net margin (TTM)-49.7%
Other income / PBT—
ROE—
Debt / equity—
Shares outstanding2.16Cr
Listed3 Jan 1996

Ownership

Promoter72.74%
Promoter Δ QoQ0.00 pp
Public27.26%
FII0.50%
DII0.00%
Pledged0.00%

Quarterly results · standalone

Q3 FY26Q4 FY26Q1 FY27Q2 FY27
Revenue (₹ Cr)7.36.87.05.8
YoY chg-36.6%+11.6%+27.4%+38.9%
Net profit (₹ Cr)(3.1)(2.3)(2.5)(5.4)
YoY chg————
Net margin-43.0%-34.4%-35.6%-93.2%
EPS-1.45-1.09-1.15-2.50

Shareholding over time

By quarter

30 Sept 2026 · promoter 72.74% · public 27.26%
30 Sept 2021: promoter 72.74%31 Dec 2021: promoter 72.74%31 Mar 2022: promoter 72.74%30 Jun 2022: promoter 72.74%30 Sept 2022: promoter 72.74%31 Dec 2022: promoter 72.72%31 Mar 2023: promoter 72.74%30 Jun 2023: promoter 72.74%30 Sept 2023: promoter 72.74%31 Dec 2023: promoter 72.74%31 Mar 2024: promoter 72.74%30 Jun 2024: promoter 72.74%30 Sept 2024: promoter 72.74%31 Dec 2024: promoter 72.74%31 Mar 2025: promoter 72.74%30 Jun 2025: promoter 72.74%30 Sept 2025: promoter 72.74%31 Dec 2025: promoter 72.74%31 Mar 2026: promoter 72.74%30 Jun 2026: promoter 72.74%30 Sept 2026: promoter 72.74%
2021-092026-09
  • Promoter
  • Public and others
Promoter
72.74%
Public
27.26%
Promoter change
0.00 pp
Filed
6 Oct 2026
FII
0.50%
DII
0.00%
Promoter pledged
0.00%

Who the public is

Mutual funds
0.00%

0.00 pp QoQ

Insurance
0.00%

0.00 pp QoQ

FPI
0.49%

0.00 pp QoQ

Retail ≤ ₹2L
10.75%

+0.23 pp QoQ

HNI > ₹2L
8.87%

-0.27 pp QoQ

NRI
1.35%

+0.05 pp QoQ

Bodies corporate
5.02%

-0.05 pp QoQ

Shareholders
8,533

+0.1% QoQ

Major holders

As of 30 Sept 2026
HolderTypeHolding
Ipca Laboratories LimitedPromoter · Corporate49.65%
HEMALATHA RAVIPromoter · Individual12.48%
AVINASH RAVIPromoter · Individual9.93%
SUN PHARMACEUTICAL INDUSTRIES LTDCorporate4.81%
GUTTIKONDA RAJASEKHARIndividual1.86%
GUTTIKONDA VARA LAKSHMIIndividual1.70%
AJAY RAVIPromoter · Individual0.52%
DR R T RAVIPromoter · Individual0.11%
ADITYA RAVIPromoter · Individual0.05%

Every promoter-group member, and each public holder above 1%, as filed.

Promoter and public shares of total equity, from the pattern filed each quarter. Institutional, pledge and public-breakdown figures come from the filing's XBRL, which most filings before Sep-2021 lack, so they are absent there rather than zero. Changes are against the previous filing.

Price-band hits

Loading…

Sessions the stock closed at the limit of its daily price band, from NSE's end-of-day list. A stock pinned at the band could not trade past it that day.

Insider trades

Insiders net, 30d
₹0
Insiders net, 90d
₹0
Promoters net, 90d
₹0
Insider buyers, 90d
0
Last promoter buy
none on record
Disclosures on record
11
0 open-market of the newest 11
By year

No open-market insider trades among the recent disclosures.

SEBI insider-trading disclosures, equity only. Dated by the day NSE broadcast them; the trade itself is often weeks earlier. The figures count promoters, directors and KMPs buying or selling on the exchange — not ESOPs, gifts, transfers within the promoter group or pledges. Stake is the holding after, as filed; the change beneath it scales that by the share counts before and after. Regulation is the PIT clause cited, and “told” the day the insider informed the company.

How the insider figures are countedPromoters buying in the open market, market-wideEvery stock on this session

Bulk & block deals · 1 Oct 2026

CSV
9 of 9 deals
By year
DateDealClientQuantityPriceValue
1 Oct 2026Sell · bulkVAIBHAV UPADHYAY1.20L66.69₹80.2L
1 Oct 2026Buy · bulkVAIBHAV UPADHYAY74266.78₹49,551
26 Nov 2024Buy · bulkGUTTIKONDA RAJASEKHAR1.44L115.85₹1.7Cr
19 Jul 2024Sell · bulkNK SECURITIES RESEARCH PRIVATE LIMITED3.71L115.16₹4.3Cr
19 Jul 2024Buy · bulkNK SECURITIES RESEARCH PRIVATE LIMITED3.71L114.96₹4.3Cr
19 Jul 2024Sell · bulkN.G.C.S. (P) LTD.1.18L115.52₹1.4Cr
19 Jul 2024Buy · bulkN.G.C.S. (P) LTD.1.18L115.39₹1.4Cr
13 Aug 2021Sell · bulkBRESCON VENTURES PRIVATE LIMITED2.25L149.07₹3.4Cr
28 Dec 2020Sell · bulkBRESCON VENTURES PRIVATE LIMITED1.00L137.75₹1.4Cr

A bulk deal is a client trading over 0.5% of the company’s shares in a day; a block deal is one large trade in the separate block window. Quantities and prices are as NSE published them, not split-adjusted.

Every stock on this session →

Takeover-code disclosures

Loading…

Filed under SEBI’s takeover regulations when a holding crosses 5% of the company, and again with every 2% it moves after that. Shares and percentages as filed.

Every stock on this session →

Short selling, lending & margin

Loading…

Shares bought on broker margin funding (MTF) and still held at the day’s end, and the amount brokers have lent against them.

Exchange surveillance

20 Nov 2026
  • Long-term ASM · Stage I · since 5 Oct 2026 — Long-term Additional Surveillance Measure: after a sustained unusual move, trades carry a higher margin and, at later stages, settle trade-for-trade.
  • Under 100 traders in 30 days · since 2 Nov 2026 — Fewer than 100 distinct investors traded it in the last 30 days.
  • Zero EPS (4 quarters) · since 6 Dec 2024 — Zero EPS over the last four quarters.
  • Loss making · since 23 Jan 2024 — The company reported a loss.

Price band: 20% · not in the F&O ban.

From NSE’s daily surveillance, price-band and position-limit files. A stock enters the F&O ban when open interest passes 95% of its market-wide position limit and leaves it below 80%; until then no new positions can be opened. CSV: measures · band changes.

Every stock on this session →

Financials · quarterly statement

Standalone
₹ crore, as filed
By year
 Q3 FY24Q4 FY24AQ1 FY25Q2 FY25Q3 FY25AQ4 FY25AQ1 FY26Q2 FY26Q3 FY26Q4 FY26AQ1 FY27Q2 FY27
Revenue from operations13.012.012.912.911.56.15.54.27.36.87.05.8
Other income0.00.20.00.10.30.30.00.00.02.00.20.0
Total income13.012.212.912.911.76.45.54.27.38.87.15.8
Total expenses18.018.018.118.719.514.710.810.310.411.29.611.2
└ Finance costs1.21.31.31.41.61.61.71.71.81.91.91.9
└ Depreciation1.71.71.71.71.71.61.61.61.61.61.61.6
Profit before tax(5.0)(5.8)(5.2)(5.8)(7.7)(8.3)(5.3)(6.1)(3.1)(2.3)(2.5)(5.4)
Tax expense0.00.00.00.00.00.00.00.00.00.00.00.0
Net profit(5.0)(5.8)(5.2)(5.8)(7.7)(8.3)(5.3)(6.1)(3.1)(2.3)(2.5)(5.4)
EPS-2.31-2.72-2.40-2.67-3.59-3.83-2.47-2.85-1.45-1.09-1.15-2.50
Net margin-38.35%-48.84%-40.12%-44.81%-67.49%-135.54%-97.14%-147.40%-42.98%-34.36%-35.58%-93.23%
PBT margin-38.35%-48.84%-40.12%-44.81%-67.49%-135.29%-97.14%-147.40%-42.98%-34.36%-35.58%-93.23%
Tax rate————————————

A audited · R restated by a later filing · negatives in parentheses. EPS and the share count are restated onto the same split-adjusted basis as the price chart, so they can be read against it; every rupee figure is exactly as filed. The balance sheet and cash flow arrive only with the half-year and annual filings, and are in their own section below. Latest filed 29 Oct 2026.

Balance sheet & cash flow · half-yearly

Standalone
₹ crore, as filed
By year

Balance sheet

 FY23H1 FY24FY24H1 FY25FY25H1 FY26FY26H1 FY27
Total assets175.0178.1178.2185.2169.0168.0163.2158.8
Current assets16.116.417.426.210.310.29.67.8
└ Cash & equivalents0.10.10.10.10.10.10.10.1
└ Other bank balances0.00.00.00.00.00.00.00.0
└ Current investments0.00.00.00.00.00.00.00.0
└ Trade receivables0.51.01.92.60.10.10.00.0
└ Inventories11.911.19.87.76.05.85.74.2
Total equity(99.5)(108.4)(119.2)(130.1)(146.2)(157.7)(162.8)(170.6)
└ Attributable to owners(99.5)(108.4)(119.2)(130.1)(146.2)(157.7)(162.8)(170.6)
└ Share capital21.621.621.621.621.621.621.621.6
Borrowings183.2187.8193.4204.6212.2219.4224.8227.0
└ Current10.09.89.943.751.055.661.372.5
└ Non-current173.2178.0183.5160.9161.3163.8163.6154.5
Trade payables15.316.719.017.518.217.513.812.4
Current liabilities49.155.461.8103.7103.5111.6113.1126.0
Total liabilities274.4286.5297.4315.4315.3325.7326.0329.4
Net debt183.2187.7193.3204.4212.1219.3224.7226.9
Current ratio0.330.300.280.250.100.090.090.06

Cash flow, year to date

 FY23H1 FY24FY24H1 FY25FY25H1 FY26FY26H1 FY27
Operating cash flow(26.5)3.12.3(6.3)(7.9)(1.7)(1.9)3.0
└ Capex(10.9)(5.7)(7.8)(2.4)(5.1)(2.2)(4.0)(1.4)
Free cash flow(37.4)(2.5)(5.5)(8.7)(13.0)(3.9)(5.9)1.6
Investing cash flow(10.9)(5.7)(7.8)(2.4)(5.0)(2.2)(3.6)(1.4)
Financing cash flow37.32.55.68.712.93.85.5(1.6)
└ Dividends paid0.00.00.00.00.00.00.00.0
└ Buybacks0.00.00.00.00.00.00.00.0
Net change in cash(0.0)(0.0)0.10.00.0(0.0)(0.0)(0.0)

From the half-year and annual results filings: the balance sheet from September 2022, the cash flow from September 2020. Those are when NSE’s XBRL began to carry each statement; earlier filings have it only in the attached PDF. Cash flow columns are year to date, so an H1 column covers April to September and an FY column the full year. Outflows are in parentheses. Net debt is borrowings less cash, bank balances and current investments; for banks, NBFCs and insurers it, debt to equity and the current ratio are left blank because their statements are not built that way.

Announcements & board meetings

Loading…

As the company filed them with NSE, newest first. Board meetings are dated by the meeting, which is usually a week or more after the intimation.

Every stock on this session →

KREBSBIO at a glance

  • KREBSBIO closed at ₹57.08 on 20 Nov 2026, -0.12% on the day, -17.5% over one year, 25.7% below its 52-week high of ₹76.85.
  • Delivery was 83.6% of traded quantity on 20 Nov 2026, the 69th percentile of its own 2,023 sessions with a reading (20-session average 73.7%, 1-year average 74.4%).
  • Market capitalisation is ₹123 crore, with no positive trailing earnings for a P/E (trailing EPS ₹-6.19).
  • Q2 FY27 results (standalone, filed 29 Oct 2026): revenue ₹6 crore (+38.9% year on year), net profit ₹-5 crore; the price moved -2.1% on the first session after.
  • Promoters held 72.74% at 30 Sept 2026, unchanged on the previous filing.
  • Q3 FY27 results are expected between 3 Feb 2027 and 13 Feb 2027, going by past filing dates — an estimate, not an announcement.

About

Macro sectorHealthcare
Basic industryPharmaceuticals
ISININE268B01013
SeriesEQ
Listed3 Jan 1996
Former namesKrebs Biochemicals Limited (until 27 Oct 2016)
NSE market cap · 17 Nov 2026₹124 Cr
Free-float market cap (NSE)₹28 Cr
Shares outstanding (NSE)2.16Cr
History from27 Oct 2016
Sessions2,438

Prices are adjusted for splits and bonuses. Delivery figures come from NSE’s daily reports and are unavailable for older sessions. Sourced from the eod2 dataset, last updated 20 Nov 2026.